Yu M - Search Results

1

[Efficacy and Survival of Venetoclax Based Regimen in the Treatment of Acute Myeloid Leukemia].

Kong FC, Qi L, Huang WF, Yu M, Zhou YL, Ji DX, Li F. Kong FC, et al. Among authors: yu m. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2023 Dec;31(6):1676-1683. doi: 10.19746/j.cnki.issn.1009-2137.2023.06.012. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2023. PMID: 38071045 Chinese.

2

[Research Progress on Biological Properties of Natural Killer Cells and Their Application in B Cell Lymphoma--Review].

Yu M, Kang J, Chen ZW, Li F. Yu M, et al. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2020 Oct;28(5):1782-1786. doi: 10.19746/j.cnki.issn.1009-2137.2020.05.058. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2020. PMID: 33067990 Review. Chinese.

3

Increased levels of serum interleukin-10 are associated with poor outcome in adult hemophagocytic lymphohistiocytosis patients.

Zhou Y, Kong F, Wang S, Yu M, Xu Y, Kang J, Tu S, Li F. Zhou Y, et al. Among authors: yu m. Orphanet J Rare Dis. 2021 Aug 4;16(1):347. doi: 10.1186/s13023-021-01973-4. Orphanet J Rare Dis. 2021. PMID: 34348761 Free PMC article.

4

Successful treatment of refractory retroperitoneal Epstein-Barr virus-positive diffuse large B-cell lymphoma with secondary hemophagocytic syndrome by sequential combination regimen of PD-1 blockade and chimeric antigen receptor T cells: a case report.

Yu M, Zhang Q, Xu S, Yin T, Li F. Yu M, et al. Anticancer Drugs. 2022 Jan 1;33(1):e769-e775. doi: 10.1097/CAD.0000000000001187. Anticancer Drugs. 2022. PMID: 34387604

5

Safety and efficacy of a humanized CD19 chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic leukemia.

Shi M, Li L, Wang S, Cheng H, Chen W, Sang W, Qi K, Li Z, Wang G, Li H, Lan J, Huang J, Fei X, Yu M, Li F, Qiao J, Wu Q, Zeng L, Jing G, Zheng J, Gale RP, Xu K, Cao J. Shi M, et al. Among authors: yu m. Am J Hematol. 2022 Jun 1;97(6):711-718. doi: 10.1002/ajh.26506. Epub 2022 Feb 25. Am J Hematol. 2022. PMID: 35179242 Free article.

6

Treatment Advances in EBV Related Lymphoproliferative Diseases.

Lv K, Yin T, Yu M, Chen Z, Zhou Y, Li F. Lv K, et al. Among authors: yu m. Front Oncol. 2022 Apr 19;12:838817. doi: 10.3389/fonc.2022.838817. eCollection 2022. Front Oncol. 2022. PMID: 35515118 Free PMC article. Review.

7

CD5+ diffuse large B-cell lymphoma has heterogeneous clinical features and poor prognosis: a single-center retrospective study in China.

Yin T, Qi L, Zhou Y, Kong F, Wang S, Yu M, Li F. Yin T, et al. Among authors: yu m. J Int Med Res. 2022 Sep;50(9):3000605221110075. doi: 10.1177/03000605221110075. J Int Med Res. 2022. PMID: 36112929 Free PMC article.

8

IL-1R8 expression in DLBCL regulates NK cell recruitment and influences patient prognosis.

Yu M, Zhang Q, Wan L, Wang S, Zou L, Chen Z, Li F. Yu M, et al. Funct Integr Genomics. 2023 Nov 1;23(4):328. doi: 10.1007/s10142-023-01254-2. Funct Integr Genomics. 2023. PMID: 37907630

9

Chidamide, Decitabine, Cytarabine, Aclarubicin, and Granulocyte Colony-stimulating Factor Therapy for Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Retrospective Study from a Single-Center.

Kong FC, Qi L, Zhou YL, Yu M, Huang WF, Li F. Kong FC, et al. Among authors: yu m. Curr Med Sci. 2023 Dec;43(6):1151-1161. doi: 10.1007/s11596-023-2805-7. Epub 2023 Dec 7. Curr Med Sci. 2023. PMID: 38057538

10

Refractory hemophagocytic lymphohistiocytosis secondary to polatuzumab vedotin plus rituximab and bendamustine.

Lv K, Kong F, Yu M, Zhou Y, Li F. Lv K, et al. Among authors: yu m. Ann Hematol. 2024 Mar;103(3):1017-1019. doi: 10.1007/s00277-023-05598-4. Epub 2023 Dec 29. Ann Hematol. 2024. PMID: 38155243 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

16,938 results

Search Page

Filters